Best Stocks Under $5 | Low-Priced Stocks for Five Dollars or Less

1. Ur Energy NYSEAMERICAN:URG

$1.42 -0.01 (-0.35%)

As of 09:55 AM Eastern

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization: $566.28 million
Consensus Rating: Buy
Consensus Price Target: $2.32 (+62.6% Upside)
Volume: 323,482 shares
Average Volume: 9.48 million shares
Today's Range: $1.42
▼
$1.44

2. CuriosityStream NASDAQ:CURI

$2.86 +0.02 (+0.85%)

As of 09:55 AM Eastern

CuriosityStream Inc operates as a factual content streaming service and media company. The company provides premium video and audio programming services in various categories of factual entertainment, including science, history, society, nature, lifestyle, and technology through direct subscription video on-demand (SVoD) platforms accessible by internet connected devices, or indirectly via distribution partners who deliver CuriosityStream content via distributor's platform or system, as well as through bundled content licenses for SVoD and linear offerings, talks and courses, and partner bulk sales. More about CuriosityStream

Market Capitalization: $169.12 million
P/E Ratio: 285.00
Consensus Rating: Buy
Consensus Price Target: $5.50 (+92.0% Upside)
Volume: 23,814 shares
Average Volume: 641,459 shares

3. iBio NASDAQ:IBIO

$1.46 +0.04 (+2.46%)

As of 09:55 AM Eastern

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBio

Market Capitalization: $72.28 million
Consensus Rating: Buy
Consensus Price Target: $5.00 (+243.6% Upside)
Volume: 78,235 shares
Average Volume: 1.21 million shares
Today's Range: $1.41
▼
$1.47

4. Larimar Therapeutics NASDAQ:LRMR

$4.19 +0.14 (+3.48%)

As of 09:55 AM Eastern

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More about Larimar Therapeutics

Market Capitalization: $435.67 million
Consensus Rating: Buy
Consensus Price Target: $11.67 (+178.4% Upside)
Volume: 45,491 shares
Average Volume: 2.73 million shares
Today's Range: $4.08
▼
$4.21

5. Inventiva NASDAQ:IVA

$4.77 +0.07 (+1.40%)

As of 09:56 AM Eastern

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More about Inventiva

Market Capitalization: $991.82 million
Consensus Rating: Buy
Consensus Price Target: $16.56 (+247.4% Upside)
Volume: 22,240 shares
Average Volume: 651,605 shares
Today's Range: $4.69
▼
$4.80

6. Uranium Royalty NASDAQ:UROY

$4.36 -0.01 (-0.32%)

As of 09:56 AM Eastern

Uranium Royalty Corp. operates as a pure-play uranium royalty company. It acquires, accumulates, and manages a portfolio of geographically diversified uranium interests. More about Uranium Royalty

Market Capitalization: $1.66 billion
P/E Ratio: 218.21
Consensus Rating: Buy
Consensus Price Target: $4.13 (-5.3% Downside)
Volume: 158,841 shares
Average Volume: 2.80 million shares

7. Niagen Bioscience NASDAQ:NAGE

$3.19 -0.02 (-0.62%)

As of 09:55 AM Eastern

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. More about Niagen Bioscience

Market Capitalization: $254.37 million
P/E Ratio: 17.75
Consensus Rating: Buy
Consensus Price Target: $10.33 (+223.9% Upside)
Volume: 7,627 shares
Average Volume: 944,687 shares

8. Inhibikase Therapeutics NASDAQ:IKT

$2.51 +0.01 (+0.24%)

As of 09:55 AM Eastern

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase Therapeutics

Market Capitalization: $347.46 million
Consensus Rating: Buy
Consensus Price Target: $5.40 (+115.5% Upside)
Volume: 49,709 shares
Average Volume: 1.21 million shares
Today's Range: $2.50
▼
$2.54

9. Palisade Bio NASDAQ:PALI

$2.00 -0.02 (-0.75%)

As of 09:56 AM Eastern

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade Bio

Market Capitalization: $347.67 million
Consensus Rating: Buy
Consensus Price Target: $9.00 (+351.1% Upside)
Volume: 30,310 shares
Average Volume: 3.69 million shares
Today's Range: $2.01
▼
$2.05

10. Inuvo NYSEAMERICAN:INUV

$0.72 +0.01 (+1.70%)

As of 09:53 AM Eastern

Inuvo, Inc engages in the advertising technology and services business primarily in the United States. It sells information technology solutions to brands, agencies, and large consolidators of advertising demand (platforms). More about Inuvo

Market Capitalization: $11.82 million
Consensus Rating: Buy
Consensus Price Target: $5.00 (+597.4% Upside)
Volume: 32,131 shares
Average Volume: 278,760 shares
Today's Range: $0.71
▼
$0.72

11. Perspective Therapeutics NYSEAMERICAN:CATX

$3.30 +0.11 (+3.45%)

As of 09:54 AM Eastern

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization: $376.70 million
Consensus Rating: Buy
Consensus Price Target: $11.50 (+248.5% Upside)
Volume: 39,129 shares
Average Volume: 2.27 million shares
Today's Range: $3.20
▼
$3.29

12. Stereotaxis NYSEAMERICAN:STXS

$1.42 -0.01 (-0.35%)

As of 09:56 AM Eastern

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about Stereotaxis

Market Capitalization: $141.78 million
Consensus Rating: Buy
Consensus Price Target: $3.70 (+161.5% Upside)
Volume: 22,552 shares
Average Volume: 602,317 shares
Today's Range: $1.40
▼
$1.43

13. Aquestive Therapeutics NASDAQ:AQST

$4.93 +0.14 (+2.81%)

As of 09:56 AM Eastern

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. More about Aquestive Therapeutics

Market Capitalization: $616.88 million
Consensus Rating: Buy
Consensus Price Target: $8.80 (+78.3% Upside)
Volume: 265,645 shares
Average Volume: 3.10 million shares
Today's Range: $4.72
▼
$4.93

14. Compugen NASDAQ:CGEN

$2.73 +0.14 (+5.41%)

As of 09:53 AM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More about Compugen

Market Capitalization: $258.12 million
P/E Ratio: 7.18
Consensus Rating: Buy
Consensus Price Target: $5.00 (+83.2% Upside)
Volume: 10,995 shares
Average Volume: 398,924 shares

15. Equillium NASDAQ:EQ

$2.21 +0.01 (+0.45%)

As of 09:55 AM Eastern

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More about Equillium

Market Capitalization: $140.14 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.57 (+242.6% Upside)
Volume: 9,031 shares
Average Volume: 618,477 shares
Today's Range: $2.20
▼
$2.23

16. Ovid Therapeutics NASDAQ:OVID

$2.84 +0.02 (+0.53%)

As of 09:56 AM Eastern

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization: $551.72 million
Consensus Rating: Moderate Buy
Consensus Price Target: $5.71 (+101.6% Upside)
Volume: 29,946 shares
Average Volume: 2.44 million shares
Today's Range: $2.84
▼
$2.89

17. Opus Genetics NASDAQ:IRD

$4.16 +0.14 (+3.35%)

As of 09:55 AM Eastern

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More about Opus Genetics

Market Capitalization: $344.24 million
Consensus Rating: Moderate Buy
Consensus Price Target: $10.69 (+156.7% Upside)
Volume: 14,696 shares
Average Volume: 923,658 shares
Today's Range: $4.07
▼
$4.21

18. Prime Medicine NASDAQ:PRME

$3.44 +0.19 (+5.69%)

As of 09:56 AM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. More about Prime Medicine

Market Capitalization: $619.40 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.47 (+117.5% Upside)
Volume: 138,966 shares
Average Volume: 2.91 million shares
Today's Range: $3.29
▼
$3.40

19. Autolus Therapeutics NASDAQ:AUTL

$2.38 +0.04 (+1.50%)

As of 09:55 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus Therapeutics

Market Capitalization: $632.13 million
Consensus Rating: Moderate Buy
Consensus Price Target: $10.00 (+321.1% Upside)
Volume: 101,064 shares
Average Volume: 1.81 million shares
Today's Range: $2.38
▼
$2.44

20. InflaRx NASDAQ:IFRX

$2.03 -0.02 (-0.98%)

As of 09:56 AM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More about InflaRx

Market Capitalization: $299.60 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.33 (+261.2% Upside)
Volume: 27,806 shares
Average Volume: 1.14 million shares
Today's Range: $2.01
▼
$2.06

21. Compass Therapeutics NASDAQ:CMPX

$2.46 +0.06 (+2.58%)

As of 09:56 AM Eastern

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass Therapeutics

Market Capitalization: $443.92 million
Consensus Rating: Moderate Buy
Consensus Price Target: $11.77 (+378.0% Upside)
Volume: 107,043 shares
Average Volume: 4.59 million shares
Today's Range: $2.39
▼
$2.46

22. Kalaris Therapeutics NASDAQ:KLRS

$4.04 -0.06 (-1.46%)

As of 09:51 AM Eastern

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. More about Kalaris Therapeutics

Market Capitalization: $96.19 million
Consensus Rating: Moderate Buy
Consensus Price Target: $18.75 (+364.1% Upside)
Volume: 5,257 shares
Average Volume: 146,380 shares
Today's Range: $4.04
▼
$4.05

23. Gold Royalty NYSEAMERICAN:GROY

$3.39 -0.07 (-1.94%)

As of 09:56 AM Eastern

Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. More about Gold Royalty

Market Capitalization: $782.22 million
P/E Ratio: 339.24
Consensus Rating: Moderate Buy
Consensus Price Target: $5.64 (+66.3% Upside)
Volume: 164,582 shares
Average Volume: 2.57 million shares

24. Nouveau Monde Graphite NYSE:NMG

$1.44 -0.01 (-0.69%)

As of 09:54 AM Eastern

Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde Graphite

Market Capitalization: $231.60 million
Consensus Rating: Moderate Buy
Consensus Price Target: $4.67 (+224.1% Upside)
Volume: 30,521 shares
Average Volume: 915,747 shares
Today's Range: $1.44
▼
$1.46

25. Tenaya Therapeutics NASDAQ:TNYA

$0.68 +0.01 (+1.23%)

As of 09:55 AM Eastern

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization: $153.15 million
Consensus Rating: Moderate Buy
Consensus Price Target: $4.00 (+485.7% Upside)
Volume: 191,493 shares
Average Volume: 3.62 million shares
Today's Range: $0.67
▼
$0.69

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Best Stocks Under $5 Right Now

1. Ur Energy NYSEAMERICAN:URG

2. CuriosityStream NASDAQ:CURI

3. iBio NASDAQ:IBIO

4. Larimar Therapeutics NASDAQ:LRMR

5. Inventiva NASDAQ:IVA

6. Uranium Royalty NASDAQ:UROY

7. Niagen Bioscience NASDAQ:NAGE

8. Inhibikase Therapeutics NASDAQ:IKT

9. Palisade Bio NASDAQ:PALI

10. Inuvo NYSEAMERICAN:INUV

11. Perspective Therapeutics NYSEAMERICAN:CATX

12. Stereotaxis NYSEAMERICAN:STXS

13. Aquestive Therapeutics NASDAQ:AQST

14. Compugen NASDAQ:CGEN

15. Equillium NASDAQ:EQ

16. Ovid Therapeutics NASDAQ:OVID

17. Opus Genetics NASDAQ:IRD

18. Prime Medicine NASDAQ:PRME

19. Autolus Therapeutics NASDAQ:AUTL

20. InflaRx NASDAQ:IFRX

21. Compass Therapeutics NASDAQ:CMPX

22. Kalaris Therapeutics NASDAQ:KLRS

23. Gold Royalty NYSEAMERICAN:GROY

24. Nouveau Monde Graphite NYSE:NMG

25. Tenaya Therapeutics NASDAQ:TNYA

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Best Stocks Under $5 Right Now

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools